Aquestive Therapeutics, Inc. (AQST) fair value analysis
Nasdaq · Updated 2026-10-19
AQST price how computed
Valuation status
No fair-value estimate yetAQST has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for AQST yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $3.78
- Sector
- Healthcare
- 12-month range
- $2.95–$7.01
- Market cap
- $474M
- From 52-week high
- -46.1%
- Shares outstanding
- 126M
- Rank in Healthcare by quality score
- #150 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Aquestive Therapeutics, Inc. is a pharmaceutical company that develops and commercializes specialty pharmaceutical products, with a focus on treatments delivered through innovative dosage forms such as films and tablets. The company operates in the United States and serves the healthcare market with medications designed to address unmet patient needs across various therapeutic areas.
AQST currently ranks #150 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $474M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $54.1M
- Net margin
- -144.6%
- EPS (TTM)
- $-0.63
- Gross margin
- 70.9%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 2.1%
- Shares outstanding
- 126M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 28 · oversold
- 50-day average
- $4.71
- 200-day average
- $4.27
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-80.0%)
2026-03 ▲ beat (+61.5%)
2025-12 ▼ miss (-100.0%)
2025-09 ▼ miss (-7.7%)
2025-06 ▲ beat (+29.4%)
2025-03 ▼ miss (-37.5%)
2024-12 ▼ miss (-21.3%)
2024-09 ▲ beat (+8.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 0 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $9.33
- Target vs last price
- +146.8%
What our data shows for AQST
- Shares are trading in the lower third of their 12-month price range of $2.95–$7.01.
- The 14-day relative strength index sits at an oversold 28.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- AQST's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the AQST conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — AQST's technical indicators shifted this week as the 50/200-day trend state moved from mixed to downtrend, while the RSI zone declined from neutral to oversold territory. The company, operating in the Healthcare sector, currently maintains an awaiting full valuation verdict. These changes suggest weakening momentum in the stock's recent price action.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is AQST stock undervalued?
TickrTrends has no fair-value estimate for AQST yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is AQST's TickrTrends verdict?
AQST is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does AQST compare to other Healthcare stocks?
AQST ranks #150 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is AQST overbought or oversold?
AQST's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does AQST report earnings next?
AQST's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does AQST usually beat earnings estimates?
Over its last 8 reported quarters AQST beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AQST?
Of 9 analysts covering AQST, 9 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $9.33 (+146.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.